COMPARE · Data as of August 24, 2026
HALO vs KRYS
Verdict: Side-by-side breakdown using the Bull Rankings model. HALO scored 79.5, KRYS scored 63.3 — HALO leads.
Compare another set
HALO
Halozyme Therapeutics, Inc.
79.5
$108.17 · $12.3B
fundamentals as of
Score gap
16.2
HALO leads
KRYS
Krystal Biotech, Inc.
63.3
$353.13 · $10.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestHALO31.7x
- Fastest growthHALO+41.2%
- Highest qualityHALO96 / 100
- Largest discount to fair valueHALO-38%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HALO
stronger →← stronger
KRYS
96
Qualityreturns · margins · balance sheet
72
97
Growthrevenue & earnings expansion
92
54
Valuevaluation vs sector peers
39
HALO is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
HALO
KRYS
$806mC+
FCF
$258mC
+41.2%A
Rev
+22.6%A-
—
D/E
0.01A
31.7xB
P/E
44.3xC
1.47B
PEG
2.20C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HALO
KRYS
38% below
Price vs fair valuelower is cheaper
22% above
~1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~16%/yr
+29%
1-yr DCF upside
-34%
+63%
5-yr DCF upside
-18%
+129%
10-yr DCF upside
+14%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HALO
Why this score
- Buying back stock
- Durable high returns
KRYS
Why this score
- Diluting shareholders
The companies
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.3b. Trading near 52-week high of $108.49 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 0% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
KRYSKrystal Biotech, Inc.
Why now
Biotechnology · market cap $10.5b. 8% off the 52-week high of $382.54. Revenue growing +23%, comfortably above the S&P median. 8 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $385.00 (implying +9% upside).
Moat
Net margin 55% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 23.7x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HALO and KRYS diverge
On the headline score the gap is 16.2 points in favor of HALO. The widest single difference is Quality, where HALO leads by 24.1 points.
- QualityHALO 95.7 · KRYS 71.6HALO +24.1
- ValueHALO 54.1 · KRYS 38.7HALO +15.4
- GrowthHALO 97.0 · KRYS 91.8HALO +5.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.